Please try another search
Roquefort Therapeutics plc, a biotechnology company, engages in the development of medicines for the treatment of cancer. The company’s pre-clinical development pipeline comprises Midkine antibodies with significance in vivo efficacy and toxicology studies; Midkine RNA therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics with novel anti-cancer approach; STAT-6 siRNA therapeutics targeting solid tumors with significance in vivo efficacy; and MK cell therapy with direct and NK-mediated anti-cancer action. Roquefort Therapeutics plc was incorporated in 2020 and is based in London, the United Kingdom.
Name | Age | Since | Title |
---|---|---|---|
Joanne Martin | - | 2023 | Member of Scientific Advisory Board |
Armand Keating | - | 2022 | Independent Chief Medical Officer & Member of Scientific Advisory Board |
Martin J. Evans | - | 2022 | Group Chief Scientific Officer & Executive Director |
Stephen Paul West | 50 | 2020 | Executive Chairman |
Michael Stein | 59 | 2021 | Independent Non-Executive Director |
Trevor Ajanthan Reginald | - | 2022 | CEO & Executive Director |
Jean Marie Duvall | 62 | 2022 | Non-Executive Director |
Darrin Matthew Disley | 55 | 2022 | Non-Executive Director |
Trevor Mervyn Jones | 81 | 2022 | Member of Scientific Advisory Board & Advisor to the Board |
Simon Sinclair | - | 2022 | Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review